Total Funding
91
19
Total FundingPost-IPO Equity raised
Growth Score
23 pts
Heat Score
-13 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
294628
Mayne Pharma Group, a specialist pharmaceutical company, optimizes and delivers oral drugs.
Acquired by 
Cosette Pharmaceuticals
John Ross: Executive Vice President, Metrics Contract ServicesPast Role: Tunnell Consulting, Principal
Stefan Cross: President, Mayne Pharma USAPast Role: Hospira, Head of Marketing
About the Company
Mayne Pharma Group Limited (Mayne Pharma) is an Australian specialist pharmaceutical company with an intellectual property portfolio built around the optimisation and delivery of oral dosage form drugs.
Mayne Pharma has a long and successful history of developing and commercializing improved pharmaceuticals and has launched and marketed numerous
products through partnerships with licensees in various countries around the world. Mayne Pharma focuses on delivering to patients improved versions of existing drugs in order to advance safety, efficacy or ease of administration.
